(Am J Obstet Gynecol 2016;214(1):6–14) Obstetric providers are challenged continuously with the evaluation of the potential benefits and harms of new diagnostic and therapeutic procedures or treatments for patients (mother and fetus), often in the setting of limited high-quality data (eg, from randomized clinical trials). Between 800,000 and 1.4 million people in the United States and >240 million people worldwide are infected with hepatitis B virus (HBV). Specific to pregnancy, an estimated prevalence of 0.7% to 0.9% for chronic hepatitis B infection among pregnant women in the United States has been reported, with >25,000 infants at risk for infection born annually to these women. The purpose of this document is to aid clinicians in counseling their patients regarding the risk and management options available after receiving a positive hepatitis B surface antigen (HBsAg) test result.
No takes yet. Share an insight, caveat, or question.
Dionne‐Odom et al. (2016) studied this question.